Proteomics International has won a key US patent for its PromarkerEndo blood test, bolstering its commercial foothold in the world’s largest healthcare market. The patented technology offers a non-invasive, accurate diagnosis of endometriosis, a condition that currently takes years to detect.
- US patent granted for PromarkerEndo diagnostic test
- Patent protection extends to 2041 in the US
- PromarkerEndo targets early-stage endometriosis diagnosis
- Patent strengthens commercialisation and licensing prospects
- Proteomics pursuing global patent coverage including Japan and Canada
US Patent Boosts Commercial Strategy for Endometriosis Test
Proteomics International Laboratories Ltd (ASX:PIQ) has achieved a pivotal milestone with the United States Patent and Trademark Office granting a patent for its PromarkerEndo blood test. This patent, covering specific protein biomarkers used to diagnose and guide treatment for endometriosis, underpins the company’s efforts to commercialise in the US, the world’s largest healthcare market.
The granted patent, titled ‘Endometriosis Biomarkers’ (US Patent No. 12674806), will protect the technology until March 2041, subject to maintenance. It safeguards Proteomics International’s intellectual property portfolio and is a critical step in positioning PromarkerEndo for licensing deals and partnerships in a market hungry for innovative, non-invasive diagnostics.
Addressing a Lengthy Diagnostic Challenge
Endometriosis affects roughly one in nine women, yet diagnosis remains notoriously slow, often taking an average of seven years and requiring invasive surgery. PromarkerEndo aims to disrupt this status quo with a blood test that has demonstrated high accuracy in published clinical studies, including for early-stage disease detection.
By enabling earlier and less invasive diagnosis, the test holds promise to improve patient outcomes and reduce healthcare costs. The technology leverages Proteomics International’s proprietary Promarker® platform, which identifies protein ‘fingerprints’ in blood samples; a novel alternative to genetic testing.
Global Patent Expansion and Commercial Execution
Proteomics International is actively securing patent protection for PromarkerEndo across multiple key jurisdictions beyond the US, including Australia, Canada, China, Europe, India, Singapore, South Korea, and Japan, where patent rights have already been granted. This broad intellectual property coverage is designed to support the company’s global commercialisation ambitions.
CEO David Morris highlighted the patent as a major validation of PromarkerEndo’s novelty and commercial potential, reinforcing the company’s strategy to transition from research to disciplined commercial execution. This follows recent organisational restructuring and a focus on distributor partnerships and reimbursement pathways in Australia and the US, reflecting a sharper commercial focus for the company.
While the announcement does not specify timelines for regulatory approvals or market rollout in the US, the patent grant significantly strengthens Proteomics International’s negotiating position for future collaborations and reimbursement discussions.
Bottom Line?
The US patent grant is a crucial step for Proteomics International’s PromarkerEndo, but the path to commercial success will hinge on regulatory progress and market adoption in a competitive diagnostics landscape.
Questions in the middle?
- How quickly will Proteomics International secure regulatory approvals and reimbursement in the US?
- What partnerships or licensing deals might emerge now that the US patent is granted?
- How will PromarkerEndo compete against existing diagnostic methods and potential new entrants?